Summary
Biogen Idec reported strong financial performance for the third quarter and first nine months of 2014, demonstrating significant revenue and profit growth compared to the prior year. Total revenues increased by 37.4% for the quarter and 51.1% for the nine months, driven by robust sales of key products, particularly TECFIDERA and TYSABRI, along with contributions from newly launched hemophilia treatments ALPROLIX and ELOCTATE. The company's profitability saw substantial improvements, with income from operations up 68.4% and net income attributable to Biogen Idec Inc. soaring by 75.7% for the quarter. Operationally, Biogen Idec continues to invest heavily in research and development, particularly in early-stage programs and pipeline advancements for multiple sclerosis and other neurological disorders. The company also expanded its strategic collaborations in Alzheimer's disease and inherited blood disorders. Despite facing ongoing competitive pressures and pricing challenges in the global pharmaceutical market, Biogen Idec maintains a strong liquidity position with substantial cash, cash equivalents, and marketable securities, enabling continued investment in growth initiatives and returning capital to shareholders through share repurchases.
Financial Highlights
54 data points| Revenue | $2.51B |
| Cost of Revenue | $302.64M |
| Gross Profit | $2.21B |
| SG&A Expenses | $570.44M |
| Operating Expenses | $1.36B |
| Operating Income | $1.15B |
| Interest Expense | $7.40M |
| Net Income | $856.90M |
| EPS (Basic) | $3.63 |
| EPS (Diluted) | $3.62 |
| Shares Outstanding (Basic) | 236.20M |
| Shares Outstanding (Diluted) | 237.00M |
Key Highlights
- 1Total revenues surged by 37.4% year-over-year to $2.51 billion for the third quarter of 2014.
- 2Net income attributable to Biogen Idec Inc. increased by 75.7% to $856.9 million for the third quarter.
- 3Diluted earnings per share grew significantly by 76.7% to $3.62 for the third quarter.
- 4Product revenues, especially from TECFIDERA and TYSABRI, showed substantial growth, contributing significantly to the top-line increase.
- 5The company launched two new hemophilia treatments, ALPROLIX and ELOCTATE, in the first three quarters of 2014, contributing initial product revenues.
- 6Research and development expenses increased by 36.4% for the nine-month period, reflecting continued investment in pipeline development.
- 7Biogen Idec maintained a strong financial position with $3.23 billion in cash, cash equivalents, and marketable securities as of September 30, 2014.